KAM
TGTX icon

Kazazian Asset Management’s TG Therapeutics TGTX Stock Holding History

Kazazian Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-12,528
Closed -$70K – 84
2018
Q3 		$70K Buy
+12,528
New +$143K 0.07% 88

Other funds holding TGTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Kazazian Asset Management's TGTX Position: Q4 2018 in Review

Kazazian Asset Management sold out of TG Therapeutics (TGTX) in Q4 2018, closing a stake of 12,528 shares — an estimated $70K sold.

Kazazian Asset Management first reported a position in TGTX in Q3 2018 and held it in 1 quarter. The position peaked at $70K in Q3 2018. 115 funds tracked by Wall St. Rank hold TGTX as of Q4 2018.

  • Kazazian Asset Management reported no remaining TG Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Kazazian Asset Management sold 12,528 TG Therapeutics shares in Q4 2018, an estimated $70K.
  • Kazazian Asset Management first reported a position in TG Therapeutics in Q3 2018 and held it in 1 quarter.
  • Kazazian Asset Management's TG Therapeutics position peaked at $70K in Q3 2018.
  • 115 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2018.

Based on Kazazian Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.